Having comprehensive or HMO health plan, evidence of preindex breast cancer surgery and preindex use of non-HER2-biologic or HER2-targeted agents were related to lower all-cause and breast cancer-specific expenditures (P < 0.05). This evidence concerns the gene ERBB2 and breast carcinoma.